



## Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

May 7, 2025

MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

### Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: [https://viaavid.webcasts.com/starthere.jsp?ei=1715314&tp\\_key=61a8c66165](https://viaavid.webcasts.com/starthere.jsp?ei=1715314&tp_key=61a8c66165). A replay of the webcast will be available on the Celcuity website following the live event.

### About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR ("PAM") pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K $\alpha$ , AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at [ClinicalTrials.gov](https://clinicaltrials.gov). A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at [www.celcuity.com](http://www.celcuity.com). Follow us on [LinkedIn](#) and [Twitter](#).

[View source version of release on GlobeNewswire.com](#)

### Contacts:

Celcuity Inc.  
Brian Sullivan, [bsullivan@celcuity.com](mailto:bsullivan@celcuity.com)  
Vicky Hahne, [vhahne@celcuity.com](mailto:vhahne@celcuity.com)  
(763) 392-0123

ICR Healthcare  
Patti Bank, [patti.bank@icrhealthcare.com](mailto:patti.bank@icrhealthcare.com)  
(415) 513-1284



News Provided by GlobeNewswire via QuoteMedia